Signaturefd LLC Has $2.15 Million Holdings in Sanofi (NASDAQ:SNY)

Signaturefd LLC boosted its stake in shares of Sanofi (NASDAQ:SNY) by 7.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,347 shares of the company’s stock after purchasing an additional 2,647 shares during the quarter. Signaturefd LLC’s holdings in Sanofi were worth $2,152,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. POM Investment Strategies LLC acquired a new stake in shares of Sanofi during the 2nd quarter worth about $25,000. Register Financial Advisors LLC bought a new stake in Sanofi during the 1st quarter worth about $29,000. Larson Financial Group LLC grew its holdings in Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after acquiring an additional 500 shares during the last quarter. Northwest Investment Counselors LLC bought a new stake in Sanofi during the 3rd quarter worth about $29,000. Finally, Palisade Asset Management LLC bought a new stake in Sanofi during the 1st quarter worth about $31,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Price Performance

NASDAQ SNY opened at $53.26 on Wednesday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The company has a market capitalization of $134.89 billion, a PE ratio of 26.76, a price-to-earnings-growth ratio of 1.57 and a beta of 0.60. The firm’s 50 day moving average is $56.13 and its 200-day moving average is $51.62.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. During the same period last year, the business earned $0.95 earnings per share. The firm’s revenue was up 7.8% on a year-over-year basis. Equities research analysts anticipate that Sanofi will post 4.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Argus increased their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.